These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36891985)

  • 1. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism.
    Kang HR; Dietrich EA; Huang PL; Lo-Ciganic WH; DeRemer CE; Park H
    Clin Transl Sci; 2023 Jun; 16(6):946-954. PubMed ID: 36891985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
    Kang HR; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Park H
    Clin Pharmacol Ther; 2022 Jul; 112(1):133-145. PubMed ID: 35420702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
    Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
    Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence.
    Hwang HG; Lee JH; Kim SA; Kim YK; Kim MS; Hong J; Yhim HY; Bang SM
    J Korean Med Sci; 2024 Sep; 39(36):e252. PubMed ID: 39315443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
    Park H; Kang HR; Huang PL; Lo-Ciganic WH; DeRemer CE; Wilson D; Dietrich EA
    Clin Transl Sci; 2023 Jan; 16(1):128-139. PubMed ID: 36200137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.
    Kang HR; Jones BL; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Wilson DL; Park H
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1219-1230. PubMed ID: 37889866
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.
    Pilkerton CS; Adelman M; Crocetti E; Xiang J; Strick V; Ponte CD; Peckens S; Jackson BP; Whipp K; Ashcraft AM
    Ann Pharmacother; 2024 Aug; 58(8):781-789. PubMed ID: 37994550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
    Coons JC; Albert L; Bejjani A; Iasella CJ
    Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Safety and Effectiveness of Direct Oral Anticoagulants and Warfarin during Chemotherapy in Cancer Patients with Venous Thromboembolism Aged 75 Years or Older: A Nationwide Inpatient Database Study.
    Iwai C; Jo T; Konishi T; Kumazawa R; Matsui H; Fushimi K; Yasunaga H
    Gerontology; 2023; 69(5):561-570. PubMed ID: 36502790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era.
    Kaneda K; Yamashita Y; Morimoto T; Chatani R; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Takada T; Otsui K; Sakamoto J; Ogihara Y; Inoue T; Usami S; Chen PM; Togi K; Koitabashi N; Hiramori S; Doi K; Mabuchi H; Tsuyuki Y; Murata K; Takabayashi K; Nakai H; Sueta D; Shioyama W; Dohke T; Nishikawa R; Ono K; Kimura T
    J Am Heart Assoc; 2024 Aug; 13(15):e034412. PubMed ID: 39082425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
    Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
    J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.
    Martin KA; Lancki N; Li C; Eyster ME; Sanfilippo K; Woller IA; Woller SC; Kreuziger LB; Rosovsky RP
    J Thromb Thrombolysis; 2023 May; 55(4):685-690. PubMed ID: 36757644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
    Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
    Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.